Avacta says salivary gland cancer drug shrinks tumour
(Alliance News) - Avacta Group PLC on Wednesday said new data demonstrated that its drug caused "robust and meaningful" tumour shrinkage in patients with salivary gland cancer. Read More
| Price | 52.50p on 25-12-2025 at 05:12:24 |
|---|---|
| Change | 0.00p 0% |
| Buy | 53.00p |
| Sell | 52.00p |
| Last Trade: | Sell 100,000.00 at 52.2025p |
| Day's Volume: | 0 |
| Last Close: | 52.50p |
| Open: | 0.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £227.67m |
| VWAP: | 0.00p |
| Shares in Issue: | 433.66m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 100,000 | 52.2025p | Ordinary |
12:37:39 - 24-Dec-25 |
| Sell* | 1,906 | 52.2372p | Ordinary |
12:28:58 - 24-Dec-25 |
| Sell* | 10,528 | 52.2398p | Ordinary |
12:28:34 - 24-Dec-25 |
| Sell* | 3,816 | 52.269p | Ordinary |
12:28:05 - 24-Dec-25 |
| Sell* | 26,396 | 52.279p | Ordinary |
12:27:38 - 24-Dec-25 |
| Sell* | 20 | 52.00p | Ordinary |
12:26:45 - 24-Dec-25 |
| Sell* | 30 | 52.00p | Ordinary |
12:25:23 - 24-Dec-25 |
| Sell* | 4,590 | 52.279p | Ordinary |
12:24:01 - 24-Dec-25 |
| Sell* | 39 | 52.295p | Ordinary |
12:23:23 - 24-Dec-25 |
| Sell* | 477 | 52.295p | Ordinary |
12:21:44 - 24-Dec-25 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
| 20th Oct 2025 7:01 am | RNS | Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am | RNS | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am | RNS | Avacta to present data at EORTC-NCI-AACR |